The Future of Cell Therapy
“We wanted to build a platform that enables stem cells to smartly act as Super Sentinel Cells™ against invasive diseases.”
— Dr. Riam Shammaa, FOUNDER & CEO
Intellistem, Inc. is a clinical-stage biotech that develops innovative cellular immune cancer therapy approaches. The Company has demonstrated the therapeutic potential and safety of its' Super Sentinel Gamma Delta Cell (SCC) Platform in Human Studies.
We are committed to increasing patient access to cell therapy by offering safer, less costly approaches for treating solid and liquid cancers.
Intellistem's SSC Cells represent a potentially attractive alternative to costly patient-derived CAR-T Cells used to treat blood cancers. SSC cells are ideal for cell therapy due to their broad antigen recognition, ability to treat solid tumors. SSC cells are produced as an allogeneic cell-based off-the-shelf pharmaceutical.
Vision
Our approach places equal weight on cell science, process, and clinical application. As a Platform Technology, SSC cells will form the basis for treating various cancers.
IntelliStem is committed to bringing revolutionary off-the-shelf cell therapy products to cancer patients that combat recurring and solid tumors. We believe our revolutionary proprietary technology will offer cancer patients a higher standard of care, including the potential for a cure at unprecedented rates.
